Dechra Pharmaceuticals (BMV:DPH N) - Cotización, noticias y análisis

Resumen de acción DPH N

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Acerca de la empresa

DPH N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 21.21%

Análisis de riesgos

Acciones altamente ilíquidas

La deuda no está bien cubierta por el flujo de caja operativo

Los márgenes de beneficio (5.5%) son inferiores a los del año pasado (11.4%)

Los accionistas han sido diluidos en el último año

Competidores de Dechra Pharmaceuticals PLC

Genomma Lab Internacional. de

BMV:LAB B

Mex$16.1b

Hubei Jumpcan Pharmaceutical

SHSE:600566

CN¥37.8b

ALK-Abelló

CPSE:ALK B

kr.33.9b

China Resources Pharmaceutical Group

SEHK:3320

HK$39.2b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Dechra Pharmaceuticals
Historical stock prices
Current Share Price	UK£858.69
52 Week High	UK£863.85
52 Week Low	UK£740.83
Beta	0.71
1 Month Change	0%
3 Month Change	n/a
1 Year Change	2.09%
3 Year Change	34.09%
5 Year Change	n/a
Change since IPO	28.77%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	DPH N	MX Pharmaceuticals	Mercado MX
7D	0%	0.9%	1.0%
1Y	2.1%	-13.7%	2.8%

Rentabilidad vs. Industria: DPH N superó al sector MX Pharmaceuticals , que obtuvo un rendimiento del -17.9% el año pasado.

Rentabilidad vs. Mercado: DPH N obtuvo unos resultados inferiores a los del mercado MX, que fue del 1.4% el año pasado.

Volatilidad de los precios

Is DPH N's price volatile compared to industry and market?
DPH N volatility
DPH N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	5.9%
10% least volatile stocks in MX Market	2.1%

Precio estable de las acciones: DPH N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de DPH N en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	1,998	Ian Page	www.dechra.com

Resumen de fundamentos de Dechra Pharmaceuticals PLC

¿Cómo se comparan los beneficios e ingresos de Dechra Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de DPH N
Capitalización bursátil	Mex$95.37b
Beneficios(TTM)	Mex$902.94m
Ingresos (TTM)	Mex$16.37b

105.6x

Ratio precio-beneficio (PE)

5.8x

Ratio precio-ventas (PS)

¿Está DPH N sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DPH N
Ingresos	UK£726.80m
Coste de los ingresos	UK£312.20m
Beneficio bruto	UK£414.60m
Otros gastos	UK£374.50m
Beneficios	UK£40.10m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

Sep 04, 2023

Beneficios por acción (BPA)	0.35
Margen bruto	57.04%
Margen de beneficio neto	5.52%
Ratio deuda/patrimonio	61.8%

¿Cómo se ha desempeñado DPH N a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.2%

Rentabilidad actual por dividendo

125%

Ratio de pagos

Resumen de acción DPH N

Recompensas

Análisis de riesgos

Competidores de Dechra Pharmaceuticals PLC

BMV:LAB B

Mex$16.1b

SHSE:600566

CN¥37.8b

CPSE:ALK B

kr.33.9b

SEHK:3320

HK$39.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Dechra Pharmaceuticals PLC

105.6x

5.8x

Beneficios e Ingresos

Dividendos

1.2%